blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2986322

EP2986322 - COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  26.06.2020
Database last updated on 27.07.2024
Most recent event   Tooltip13.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Signal Pharmaceuticals, LLC
10300 Campus Point Drive
Suite 100
San Diego, CA 92121 / US
[2016/08]
Inventor(s)01 / HEGE, Kristen, Mae
616 Howard Ave.
Burlingame, CA 94010 / US
02 / CHOPRA, Rajesh
Flat 5 Ruvigny Mansions
Embankment, Putney
London SW15 1 LE / GB
03 / RAYMON, Heather
3520 Vista de la Orilla
San Diego, CA 92117 / US
 [2019/29]
Former [2016/08]01 / HEGE, Kristen, Mae
616 Howard Ave.
Burlingame, CA 94010 / US
02 / CHOPRA, Rajesh
54 Eggers Court
Summit, NJ 07901 / US
03 / RAYMON, Heather
3520 Vista de la Orilla
San Diego, CA 92117 / US
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2016/08]
Application number, filing date14725328.016.04.2014
[2016/08]
WO2014US34321
Priority number, dateUS201361813089P17.04.2013         Original published format: US 201361813089 P
US201361908408P25.11.2013         Original published format: US 201361908408 P
[2016/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014172436
Date:23.10.2014
Language:EN
[2014/43]
Type: A1 Application with search report 
No.:EP2986322
Date:24.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2014 takes the place of the publication of the European patent application.
[2016/08]
Search report(s)International search report - published on:EP23.10.2014
ClassificationIPC:A61K45/06, A61K31/4985, A61P35/00, A61P35/02
[2016/08]
CPC:
A61K31/517 (EP,US); A61K31/4985 (EP,US); A61K39/3955 (EP,US);
A61K45/06 (EP,US); A61P35/00 (EP); A61P35/02 (EP);
A61P43/00 (EP) (-)
C-Set:
A61K31/4985, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (US,EP);
A61K39/3955, A61K2300/00 (US,EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/08]
TitleGerman:KOMBINATIONSTHERAPIE MIT EINEM TOR-KINASEINHIBITOR UND EINER 5-SUBSTITUIERTEN CHINAZOLINONVERBINDUNG ZUR BEHANDLUNG VON KREBS[2016/08]
English:COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER[2016/08]
French:POLYTHÉRAPIE COMPRENANT UN INHIBITEUR DE KINASE TOR ET UN COMPOSÉ DE QUINAZOLINONE SUBSTITUÉ EN 5 POUR LE TRAITEMENT DU CANCER[2016/08]
Entry into regional phase05.11.2015National basic fee paid 
05.11.2015Designation fee(s) paid 
05.11.2015Examination fee paid 
Examination procedure05.11.2015Examination requested  [2016/08]
29.04.2016Amendment by applicant (claims and/or description)
30.06.2020Despatch of a communication from the examining division (Time limit: M04)
29.10.2020Reply to a communication from the examining division
18.08.2022Despatch of a communication from the examining division (Time limit: M04)
14.12.2022Reply to a communication from the examining division
Fees paidRenewal fee
27.04.2016Renewal fee patent year 03
27.04.2017Renewal fee patent year 04
27.04.2018Renewal fee patent year 05
29.04.2019Renewal fee patent year 06
27.04.2020Renewal fee patent year 07
15.04.2021Renewal fee patent year 08
21.03.2022Renewal fee patent year 09
14.03.2023Renewal fee patent year 10
13.03.2024Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2008051493  (SIGNAL PHARM LLC [US], et al) [Y] 1-19 * page 56, line 11, paragraph 262 * * claim - * * page 56, line 1 * * page 54, paragraph 257 *;
 [Y]WO2010057048  (CALISTOGA PHARMACEUTICALS INC [US], et al) [Y] 1-19 * claim - * * page 16, paragraph 144 - page 17, paragraph 146 * * page 17, line 23 *;
 [Y]WO2010062571  (SIGNAL PHARM LLC [US], et al) [Y] 1-19 * page 55, paragraph 106 * * claims 48, 52, 58-60 * * page 34, paragraph 76 - page 43, paragraph 77 * * claim - * * pages 60-62, paragraphs 112-117 * * page 64, paragraph 122 - page 75, paragraph 140 *;
 [Y]WO2011053518  (SIGNAL PHARM LLC [US], et al) [Y] 1-19 * pages 61-62, paragraphs 108-109 * * claim - *;
 [Y]US2012028972  (WONG LILLY [US], et al) [Y] 1-19 * claims 10-11 * * page 4, paragraph 41 *;
 [YD]US2012230983  (MULLER GEORGE W [US], et al) [YD] 1-19 * claims 31-32, 61-62 * * claim - * * page 4, paragraph 34 * * page 4, paragraphs 40, 42 * * page 17, paragraph 233 *;
 [YP]WO2013059396  (SIGNAL PHARM LLC [US]) [YP] 1-19* claim - *;
 [YP]WO2013082344  (SIGNAL PHARM LLC [US]) [YP] 1-19 * claim - *;
 [A]  - COSTA ET AL, "Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma", CANCER TREATMENT REVIEWS, SAUNDERS, US, (20070126), vol. 33, no. 1, doi:10.1016/J.CTRV.2006.10.004, ISSN 0305-7372, pages 78 - 84, XP005853740 [A] 1-19 * abstract *

DOI:   http://dx.doi.org/10.1016/j.ctrv.2006.10.004
 [A]  - JOHNSON A J ET AL, "ADVANCES IN THE THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA", CURRENT OPINION IN HEMATOLOGY, RAPID SCIENCE PUBLISHERS, PHILADELPHIA, PA, US, (20030701), vol. 10, no. 4, doi:10.1097/00062752-200307000-00008, ISSN 1065-6251, pages 297 - 305, XP009040617 [A] 1-19 * abstract * * page 302, column left, paragraph last *

DOI:   http://dx.doi.org/10.1097/00062752-200307000-00008
by applicantUS2009093504
 US7635700
 US2010029610
 WO2010137547
 US7879984
 US2011129412
 US2011223157
 US8057793
 US8084582
 US8101179
 US8110578
 US2012034185
 US8147832
 US8153125
 US2012134990
 US2012183545
 US2012230983
 US2013142873
 US8569494
    - COHEN, NATURE, (2002), vol. 1, pages 309 - 315
    - COHEN, EUR. J BIOCHEM., (2001), vol. 268, pages 5001 - 5010
    - "Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems", Handbook of Experimental Pharmacology, SPRINGER, (2005), vol. 167
    - SRIDHAR ET AL., PHARMACEUTICAL RESEARCH, (2000), vol. 17, no. 11, pages 1345 - 1353
    - PARK ET AL., CELL, (2000), vol. 101, no. 7, pages 777 - 787
    - FABBRO ET AL., PHARMACOLOGY & THERAPEUTICS, (2002), vol. 93, pages 79 - 98
    - FABBRO ET AL., PHANNACOLOGY & THERAPEUTICS, (2002), vol. 93, pages 79 - 98
    - GEORGAKIS; YOUNES, EXPERT REV. ANTICANCER THER., (2006), vol. 6, no. 1, pages 131 - 140
    - JACKSON, S. P.; BARTEK, J., "The DNA-damage response in human biology and disease", NATURE, (2009), vol. 461, doi:doi:10.1038/nature08467, pages 1071 - 1078, XP055070409

DOI:   http://dx.doi.org/10.1038/nature08467
    - HOEIJMAKERS, J. H., "J. Genome maintenance mechanisms for preventing cancer", NATURE, (2001), vol. 411, pages 366 - 374
    - VAN GENT, D. C.; HOEIJMAKERS, J. H.; KANAAR, R., "Chromosomal stability and the DNA double-stranded break connection", NAT REV GENET, (2001), vol. 2, doi:doi:10.1038/35056049, pages 196 - 206, XP001099022

DOI:   http://dx.doi.org/10.1038/35056049
    - COLLIS, S. J.; DEWEESE, T. L.; JEGGO P. A.; PARKER, A.R., "The life and death ofDNA-PK", ONCOGENE, (2005), vol. 24, pages 949 - 961
    - TAKATA, M.; SASAKI, M. S.; SONODA, E.; MORRISON, C.; HASHIMOTO, M.; UTSUMI, H. ET AL., "Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells", EMBO J, (1998), vol. 17, doi:doi:10.1093/emboj/17.18.5497, pages 5497 - 5508, XP002267382

DOI:   http://dx.doi.org/10.1093/emboj/17.18.5497
    - HABER, J. E., "Partners and pathways repairing a double-strand break", TRENDS GENET, (2000), vol. 16, doi:doi:10.1016/S0168-9525(00)02022-9, pages 259 - 264, XP004200111

DOI:   http://dx.doi.org/10.1016/S0168-9525(00)02022-9
    - COLLIS, S. J.; DEWEESE, T. L.; JEGGO P. A.; PARKER, A.R., "The life and death of DNA-PK", ONCOGENE, (2005), vol. 24, doi:doi:10.1038/sj.onc.1208332, pages 949 - 961, XP008052096

DOI:   http://dx.doi.org/10.1038/sj.onc.1208332
    - SMITH, G. C. M.; JACKSON, S.P, "The DNA-dependent protein kinase", GENES DEV, (1999), vol. 13, pages 916 - 934
    - JEGGO, P.A.; CALDECOTT, K.; PIDSLEY, S.; BANKS, G.R., "Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors", CANCER RES, (1989), vol. 49, pages 7057 - 7063
    - "ch. 12, sect. 10,", STOCKDALE, Medicine, (1998), vol. 3
    - HIGGINS, J.J. ET AL., NEUROLOGY, (2004), vol. 63, pages 1927 - 1931
    - JO, S ET AL., J. NEUROCHEM, (2005), vol. 94, pages 1212 - 1224
    - HOHBERGER B. ET AL., FEBS LETT, (2009), vol. 583, pages 633 - 637
    - ANGERS S. ET AL., NATURE, (2006), vol. 443, pages 590 - 593
    - ITO, T. ET AL., SCIENCE, (2010), vol. 327, pages 1345 - 1350
    - WILEN, S. H. ET AL., TETRAHEDRON, (1977), vol. 33, page 2725
    - WILEN, S. H., Tables ofResolving Agents and Optical Resolutions, UNIV. OF NOTRE DAME PRESS, (1972), page 268
    - CHESON BD; PFISTNER B; JUWEID, ME, "Revised Response Criteria for Malignant Lymphoma", J. CLIN. ONCOL, (2007), pages 579 - 586
    - HALLEK M; CHESON BD; CATOVSKY D ET AL., BLOOD, (2008), vol. 12, no. 111, pages 5446 - 5456
    - DURIE BGM; HAROUSSEAU J-L; MIGUEL JS ET AL., "International uniform response criteria for multiple myeloma", LEUKEMIA, (2006), vol. 10, no. 10, pages 1 - 7
    - THEREASSE P. ET AL., "New Guidelines to Evaluate the Response to Treatment in Solid Tumors", J. OF THE NATIONAL CANCER INSTITUTE, (2000), pages 205 - 216
    - EISENHAUER E.A.; THERASSE P.; BOGAERTS J. ET AL., "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1", EUROPEAN J. CANCER, (2009), doi:doi:10.1016/j.ejca.2008.10.026, pages 228 - 247, XP025841550

DOI:   http://dx.doi.org/10.1016/j.ejca.2008.10.026
    - WEN P.; MACDONALD, DR.; REARDON, DA. ET AL., "Updated response assessment criteria for highgrade gliomas: Response assessment in neuro-oncology working group", J CLIN ONCOL, (2010), vol. 28, pages 1963 - 1972
    - BINDER ET AL., BLOOD, (2006), vol. 108, no. 6, pages 1975 - 1978
    - DEANS ET AL., BLOOD, (2008), vol. 111, no. 4, page 2492
    - PEROSA ET AL., J IMMUNOL., (2009), vol. 182, pages 416 - 423
    - PAUL,, Fundamental Immunology Second Edition,, RAVEN PRESS, (1989), pages 332 - 336
    - CHESON B; PFISTNER B; JUWEID M ET AL., "Revised Response Criteria for Malignant Lymphoma", J CLIN ONCOL, (2007), vol. 25, no. 5, pages 579 - 586
    - CHESON ET AL., J CLIN ONCOL, (2007), vol. 25, no. 5, pages 579 - 586
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.